8-K: Compass Therapeutics Announces Positive Phase 2/3 Data for Tovecimig in Biliary Tract Cancer and Provides Corporate Update

Compass Therapeutics reports positive topline results for Tovecimig in biliary tract cancer, advances its pipeline, and maintains a strong cash position.

Summary

• Compass Therapeutics announced its first quarter 2025 financial results and provided a corporate update.
• Tovecimig met the primary endpoint in a Phase 2/3 study for biliary tract cancer (BTC), showing a 17.1% overall response rate (ORR) compared to 5.3% for paclitaxel alone.
• The first patient was dosed in an Investigator Sponsored Trial (IST) evaluating tovecimig in first-line BTC.
• The company successfully completed a pre-IND meeting for CTX-10726, with an IND filing expected in Q4 2025 and clinical data in 2026.
• CTX-8371's Phase 1 dose-escalation study advanced to the fourth dosing cohort, with data expected in the second half of 2025.
• Compass ended Q1 with $113 million in cash and marketable securities, providing a cash runway into the first quarter of 2027.
• Net loss for the quarter ended March 31, 2025, was $16.6 million, or $0.12 per share.
• Research and Development (R&D) expenses were $13.1 million for the quarter ended March 31, 2025.
• General and Administrative (G&A) expenses were $4.9 million for the quarter ended March 31, 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook due to the positive Phase 2/3 data for Tovecimig and the company's strong cash position. However, the increased net loss and expenses temper the overall sentiment.

Positives

• Tovecimig met its primary endpoint in the Phase 2/3 trial for biliary tract cancer.
• The company has a strong cash position of $113 million, providing a cash runway into the first quarter of 2027.
• CTX-10726 is progressing towards an IND filing in Q4 2025.
• CTX-8371 is advancing through its Phase 1 dose-escalation study.

Negatives

• The company reported a net loss of $16.6 million for the quarter ended March 31, 2025, compared to $10.8 million for the same period in 2024.
• R&D expenses increased by $3.6 million, or 37%, compared to the same period in 2024.
• G&A expenses increased by $1.7 million or 51%, compared to the same period in 2024.

Risks

• The company's ability to raise additional funding is a risk factor.
• The inherent uncertainties associated with developing product candidates and operating as a development stage company pose risks.
• Competition in the industry and market conditions could impact the company's performance.

Future Outlook

Compass Therapeutics expects to continue advancing its product candidates, including Tovecimig, CTX-10726, CTX-471 and CTX-8371, through clinical development. The company anticipates an IND filing for CTX-10726 in Q4 2025 and clinical data in 2026. Data from the CTX-8371 Phase 1 study is expected in the second half of 2025. The company's cash runway is expected to last into the first quarter of 2027.

Management Comments

• 'Were proud of the progress weve made this quarter, especially the achievement of the primary endpoint in our COMPANION-002 trial,' said Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors.
• Dr. Schuetz also stated that the company continues to advance CTX-10726 and CTX-8371, and that the balance sheet remains strong.

Industry Context

The announcement highlights the growing interest in bispecific antibodies for cancer therapy, particularly those targeting angiogenesis and immune checkpoints. The success of Tovecimig in biliary tract cancer could position Compass Therapeutics as a key player in this space. The development of CTX-10726, a PD-1 x VEGF-A bispecific antibody, aligns with the industry trend of combining checkpoint inhibition with anti-angiogenic therapies.

Comparison to Industry Standards

• The 17.1% ORR for Tovecimig in biliary tract cancer compares favorably to the 5.3% ORR for paclitaxel alone, demonstrating a clinically meaningful improvement.
• Other companies developing bispecific antibodies targeting similar pathways include Regeneron with its REGN3500 (VEGF x Ang2) and Roche with its RO7086340 (PD-L1 x VEGF).
• The expected IND filing for CTX-10726 in Q4 2025 puts Compass Therapeutics on a similar timeline to other companies developing PD-1 x VEGF-A bispecific antibodies.

Stakeholder Impact

• Shareholders may react positively to the positive clinical data and strong cash position.
• Employees may be encouraged by the company's progress and future prospects.
• Patients with biliary tract cancer may benefit from the potential approval of Tovecimig.
• Suppliers and creditors can be reassured by the company's financial stability.

Next Steps

• The company expects to report analyses of secondary endpoints for Tovecimig in Q4 2025.
• Compass Therapeutics plans to submit an IND for CTX-10726 in Q4 2025.
• The company expects to share data from the CTX-8371 Phase 1 study in the second half of 2025.
• Phase 2 trial initiation of CTX-471 in patients with tumors expressing NCAM (CD56) is expected in the second half of 2025.
• The previously planned Phase 2 colorectal cancer study will be replaced by a Phase 2 basket study of tovecimig, which is expected to begin following the analyses of the secondary endpoint data from the COMPANION-002 BTC trial.

Key Dates

Keywords

Tovecimig, CTX-10726, CTX-8371, biliary tract cancer, bispecific antibody, oncology, clinical trial, Compass Therapeutics, financial results, R&D, IND filing, cash runway